Navigation Links
Sharon McCudden Named KePRO Director of Business Process Improvement & Compliance
Date:1/24/2008

Improving integrated medical management with use of Six Sigma Model

HARRISBURG, Pa., Jan. 24 /PRNewswire/ -- The Keystone Peer Review Organization, Inc. (KePRO), a rapidly growing national, total population medical management firm, recently appointed Sharon McCudden to the position of Director of Business Process Improvement and Compliance. Reporting to Joseph A. Dougher, Chief Executive Officer, Ms. McCudden will build and implement a successful adoption plan to expand the use of Six Sigma in collaboration with all organizations across the enterprise.

KePRO and its subsidiary, HealthQuest, have been providing integrated medical management solutions to public and commercial clients since 1985, delivering excellent customer service and substantial return on investment. As the company continues to expand, Dougher emphasizes that "KePRO has long been known for our high level of service commitment, providing efficient, cost- effective solutions. Sharon will extend her project management and Six Sigma expertise throughout the KePRO family of companies to eliminate process barriers, make us even more competitive, and increase customer satisfaction through improved service delivery."

Adopting the Six Sigma (DMAI2C) Model Process Improvement, Ms. McCudden will spearhead integrated medical management by building and deploying state of the art systems to improve effectiveness and efficiency internally and externally. Her mission is to leverage automation and integrate all components of medical management through quality initiatives.

Ms. McCudden is up to the challenge, possessing strong leadership abilities and having program, project, and process management acumen, as well as proven business development, procurement, and information technology expertise. "I have always possessed an unwavering commitment to quality and customer satisfaction," said McCudden. "KePRO has that same passion. This is a tremendous opportunity for us to marry our co
'/>"/>

SOURCE KePRO
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Dave Perbix Named Vice President, Occupational Health Sales and Marketing for Kaiser Permanente
2. CBaySystems Again Named to the Baltimore List of Fastest Growing Companies
3. Dr. Bart Harmon Named Chief Medical Officer for Harris Corporations Healthcare Solutions Business
4. Kenneth A. Sylvia Named as New Publisher of Current Psychiatry
5. Ravenell named recipient of grant from Robert Wood Johnson Foundation
6. Brown named Center of Excellence in Geriatric Medicine and Training
7. International Aid Named as a MinistryWatch.com Shining Light Christian Ministry
8. Rhodes Named Head of Health Plan Administration Company TCC
9. PartsSource Named 2007 Weatherhead 100 Award Winner
10. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
11. Florida Boy Named CNN Heroes Viewers Choice Winner
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 2Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 3Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 4Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 5Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 6Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 7Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 8Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 2Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 3